Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Profile

Daniel Bowles

Concepts (339)

Concepts are derived automatically from a person's publications.

Cloud
Categories
Timeline
Details
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Antineoplastic Agents
29
2024
1941
3.720
 Why?
Head and Neck Neoplasms
16
2023
478
3.250
 Why?
Salivary Gland Neoplasms
8
2023
33
3.240
 Why?
Carcinoma, Squamous Cell
14
2019
610
2.460
 Why?
Protein Kinase Inhibitors
12
2024
803
2.290
 Why?
Pyridines
10
2024
421
2.260
 Why?
Thyroid Neoplasms
8
2024
264
2.040
 Why?
Neoplasm Recurrence, Local
7
2023
878
1.950
 Why?
Molecular Targeted Therapy
7
2021
354
1.900
 Why?
Carcinoma, Non-Small-Cell Lung
7
2022
975
1.770
 Why?
Antineoplastic Combined Chemotherapy Protocols
13
2019
1374
1.710
 Why?
Protein-Tyrosine Kinases
4
2021
403
1.610
 Why?
Anilides
6
2024
68
1.540
 Why?
Neoplasms
17
2022
2147
1.530
 Why?
Gonanes
7
2016
28
1.510
 Why?
Biomarkers, Tumor
8
2020
1053
1.460
 Why?
Proto-Oncogene Proteins
6
2021
615
1.460
 Why?
Lung Neoplasms
9
2022
2222
1.450
 Why?
Adenocarcinoma
7
2024
794
1.430
 Why?
Thyroid Carcinoma, Anaplastic
3
2020
35
1.410
 Why?
Cetuximab
7
2018
99
1.400
 Why?
Phosphatidylinositol 3-Kinases
8
2017
332
0.930
 Why?
Carcinoma
3
2019
201
0.820
 Why?
Neoplasm Staging
15
2019
1207
0.790
 Why?
Phytotherapy
2
2012
68
0.780
 Why?
Drugs, Investigational
2
2011
31
0.770
 Why?
Mutation
12
2021
3420
0.770
 Why?
Neoplasms, Second Primary
1
2021
93
0.700
 Why?
Disease-Free Survival
10
2017
634
0.700
 Why?
Papillomaviridae
4
2019
100
0.700
 Why?
Antineoplastic Agents, Immunological
2
2018
157
0.700
 Why?
Pyrazoles
4
2022
364
0.700
 Why?
Carcinoma, Renal Cell
3
2017
174
0.690
 Why?
Taxoids
3
2015
95
0.680
 Why?
Humans
84
2024
117083
0.680
 Why?
Hedgehog Proteins
3
2015
174
0.670
 Why?
Colorectal Neoplasms
2
2016
630
0.630
 Why?
Marijuana Smoking
2
2012
219
0.630
 Why?
Tumor Suppressor Proteins
2
2018
286
0.630
 Why?
Middle Aged
40
2021
27183
0.620
 Why?
Kidney Neoplasms
3
2017
335
0.600
 Why?
Aged
36
2024
19367
0.590
 Why?
Carcinoma, Mucoepidermoid
1
2017
17
0.590
 Why?
Ubiquitin Thiolesterase
1
2017
38
0.570
 Why?
Carcinoma, Transitional Cell
4
2017
54
0.570
 Why?
Cisplatin
5
2018
272
0.560
 Why?
Carcinoma, Ductal
1
2016
11
0.560
 Why?
Adenoma, Pleomorphic
1
2016
8
0.560
 Why?
Gene Rearrangement
2
2018
140
0.560
 Why?
Sulfones
2
2014
97
0.550
 Why?
Glycine
2
2014
161
0.550
 Why?
Maximum Tolerated Dose
5
2017
183
0.510
 Why?
Drug Resistance, Neoplasm
7
2021
669
0.490
 Why?
Melanoma
1
2021
664
0.480
 Why?
Enzyme Inhibitors
3
2014
775
0.470
 Why?
Drug Interactions
6
2017
346
0.470
 Why?
Quinolines
4
2024
128
0.470
 Why?
Signal Transduction
8
2018
4606
0.460
 Why?
Pyrroles
1
2014
186
0.460
 Why?
Pyrimidines
4
2022
379
0.450
 Why?
Male
41
2022
56694
0.450
 Why?
Gene Fusion
3
2023
18
0.450
 Why?
Genetic Variation
1
2018
900
0.430
 Why?
Receptor Protein-Tyrosine Kinases
2
2012
229
0.430
 Why?
Female
42
2022
60665
0.430
 Why?
Lymph Nodes
4
2017
430
0.430
 Why?
Indazoles
3
2019
59
0.420
 Why?
Treatment Outcome
15
2024
9263
0.420
 Why?
Class I Phosphatidylinositol 3-Kinases
4
2017
80
0.410
 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
2012
92
0.400
 Why?
Quinazolines
1
2013
244
0.400
 Why?
Aged, 80 and over
14
2020
6460
0.400
 Why?
Neoplasm Metastasis
6
2021
534
0.380
 Why?
Cannabinoids
1
2011
116
0.350
 Why?
Prognosis
9
2021
3390
0.340
 Why?
Adult
22
2022
31009
0.330
 Why?
Papillomavirus Infections
3
2022
264
0.320
 Why?
ErbB Receptors
4
2017
569
0.310
 Why?
Pharmacogenomic Variants
2
2018
34
0.300
 Why?
Proto-Oncogene Proteins c-ret
3
2022
25
0.300
 Why?
Nitriles
2
2022
154
0.300
 Why?
Urologic Neoplasms
2
2017
25
0.290
 Why?
Carcinoma, Ductal, Breast
1
2007
77
0.290
 Why?
Mitoxantrone
1
2006
12
0.280
 Why?
Enterobacter
1
2006
7
0.280
 Why?
Acute Kidney Injury
3
2018
690
0.280
 Why?
Tooth Diseases
1
2006
14
0.280
 Why?
Gene Expression Profiling
5
2018
1588
0.270
 Why?
Esophageal and Gastric Varices
1
2006
35
0.270
 Why?
Enterobacteriaceae Infections
1
2006
33
0.270
 Why?
Benzamides
2
2019
173
0.270
 Why?
Salivary Glands
2
2023
33
0.260
 Why?
Oropharyngeal Neoplasms
2
2016
51
0.260
 Why?
Animals
15
2019
32741
0.260
 Why?
Clinical Trials as Topic
3
2018
957
0.260
 Why?
Chemoradiotherapy
4
2020
199
0.260
 Why?
Registries
2
2016
1789
0.250
 Why?
Immunotherapy
2
2023
491
0.250
 Why?
Cannabis
1
2011
381
0.250
 Why?
Antibodies, Monoclonal, Humanized
3
2014
667
0.250
 Why?
Receptors, Estrogen
1
2007
375
0.250
 Why?
Xenograft Model Antitumor Assays
6
2019
730
0.240
 Why?
Urinary Bladder Neoplasms
2
2017
200
0.240
 Why?
Bacteremia
1
2006
159
0.240
 Why?
Gene Expression Regulation, Neoplastic
3
2019
1159
0.240
 Why?
Liver Cirrhosis
1
2006
245
0.240
 Why?
Carcinoma, Adenoid Cystic
1
2023
18
0.230
 Why?
Combined Modality Therapy
4
2018
1144
0.230
 Why?
Administration, Oral
3
2014
744
0.230
 Why?
Iodine Radioisotopes
4
2024
126
0.220
 Why?
Referral and Consultation
1
2007
640
0.210
 Why?
Phenylurea Compounds
3
2024
84
0.210
 Why?
Breast Neoplasms
2
2019
1883
0.210
 Why?
Survival Rate
5
2021
1679
0.210
 Why?
Phenylthiohydantoin
1
2022
40
0.210
 Why?
Chemotherapy, Adjuvant
3
2017
343
0.200
 Why?
Radiation Pneumonitis
1
2021
26
0.200
 Why?
Drug Evaluation, Preclinical
2
2013
170
0.200
 Why?
Survival Analysis
4
2020
1240
0.200
 Why?
Carcinoma, Neuroendocrine
1
2021
29
0.190
 Why?
TOR Serine-Threonine Kinases
2
2016
366
0.190
 Why?
Adrenal Cortex Neoplasms
1
2021
48
0.190
 Why?
Adrenocortical Carcinoma
1
2021
47
0.190
 Why?
Disease Susceptibility
2
2020
327
0.180
 Why?
United States
8
2021
12385
0.180
 Why?
SEER Program
1
2021
202
0.180
 Why?
Cystectomy
2
2017
32
0.180
 Why?
Gene Expression
2
2015
1466
0.180
 Why?
Receptors, Nerve Growth Factor
1
2019
15
0.180
 Why?
Leukemia, Myeloid, Acute
1
2006
539
0.180
 Why?
Kaplan-Meier Estimate
3
2017
825
0.180
 Why?
Lymph Node Excision
2
2017
146
0.170
 Why?
DNA Mutational Analysis
2
2018
373
0.170
 Why?
Positron Emission Tomography Computed Tomography
1
2020
70
0.170
 Why?
Radiosurgery
1
2022
316
0.170
 Why?
Tracheal Neoplasms
1
2019
12
0.170
 Why?
Prostatic Neoplasms
1
2006
936
0.170
 Why?
Palliative Care
2
2018
623
0.170
 Why?
Genomics
3
2021
658
0.160
 Why?
Smad4 Protein
1
2019
37
0.160
 Why?
Genetic Heterogeneity
1
2019
55
0.160
 Why?
Benzazepines
1
2018
37
0.160
 Why?
Alphapapillomavirus
2
2016
38
0.160
 Why?
Disease Management
2
2020
560
0.160
 Why?
Chromosome Aberrations
1
2019
135
0.160
 Why?
Risk
1
2021
842
0.160
 Why?
DNA Mismatch Repair
1
2018
37
0.160
 Why?
Receptor, ErbB-2
2
2019
303
0.150
 Why?
Paraffin Embedding
1
2017
22
0.150
 Why?
Tissue Fixation
1
2017
28
0.150
 Why?
Formaldehyde
1
2017
47
0.150
 Why?
Oncogenes
1
2018
110
0.150
 Why?
Erlotinib Hydrochloride
1
2017
66
0.150
 Why?
Nasopharyngeal Neoplasms
1
2017
16
0.150
 Why?
Smokers
1
2018
148
0.150
 Why?
Neoplasm Grading
1
2018
247
0.150
 Why?
Radiotherapy, Intensity-Modulated
1
2018
128
0.150
 Why?
Gene Deletion
1
2019
356
0.150
 Why?
Health Services Needs and Demand
1
2019
249
0.150
 Why?
Young Adult
5
2021
10680
0.150
 Why?
DNA, Neoplasm
1
2017
151
0.150
 Why?
Induction Chemotherapy
1
2017
58
0.140
 Why?
Patient Navigation
1
2018
63
0.140
 Why?
Hospice and Palliative Care Nursing
1
2018
68
0.140
 Why?
Chemoradiotherapy, Adjuvant
1
2016
42
0.140
 Why?
Salivary Ducts
1
2016
4
0.140
 Why?
Gene Frequency
1
2018
507
0.140
 Why?
Retrospective Studies
8
2021
12843
0.140
 Why?
Computational Biology
2
2018
540
0.140
 Why?
Disease Progression
4
2018
2467
0.140
 Why?
Muscle, Smooth
1
2017
151
0.140
 Why?
Nomograms
1
2016
43
0.140
 Why?
Carboplatin
1
2016
140
0.140
 Why?
Laryngeal Neoplasms
1
2016
39
0.140
 Why?
Population Surveillance
1
2019
406
0.130
 Why?
Dose-Response Relationship, Drug
3
2017
1889
0.130
 Why?
Database Management Systems
1
2016
49
0.130
 Why?
Incidence
2
2019
2378
0.130
 Why?
Angiopoietin-1
1
2015
10
0.130
 Why?
Angiopoietin-2
1
2015
13
0.130
 Why?
Bone Neoplasms
1
2017
195
0.130
 Why?
Genetic Testing
1
2018
384
0.130
 Why?
Radiotherapy
1
2016
186
0.130
 Why?
Zinc Finger Protein GLI1
1
2014
21
0.130
 Why?
Retreatment
1
2014
71
0.120
 Why?
Hospice Care
1
2018
181
0.120
 Why?
Piperazines
2
2018
314
0.120
 Why?
Neoplasms, Unknown Primary
1
2014
12
0.120
 Why?
Response Evaluation Criteria in Solid Tumors
1
2014
15
0.120
 Why?
Neoplastic Stem Cells
1
2018
335
0.120
 Why?
Paclitaxel
1
2015
192
0.120
 Why?
Pilot Projects
2
2015
1396
0.120
 Why?
Proto-Oncogene Proteins c-akt
1
2016
406
0.120
 Why?
Patient Satisfaction
1
2018
595
0.120
 Why?
Sulfonamides
1
2017
451
0.120
 Why?
High-Throughput Nucleotide Sequencing
1
2017
455
0.120
 Why?
Prospective Studies
6
2024
6391
0.120
 Why?
Proportional Hazards Models
4
2017
1105
0.110
 Why?
Promoter Regions, Genetic
1
2018
1141
0.110
 Why?
ras Proteins
1
2014
140
0.110
 Why?
Veratrum Alkaloids
1
2013
18
0.110
 Why?
PTEN Phosphohydrolase
1
2014
143
0.110
 Why?
Proto-Oncogene Proteins p21(ras)
1
2014
232
0.110
 Why?
Cell Cycle Proteins
2
2014
563
0.110
 Why?
Biomarkers
3
2018
3550
0.110
 Why?
Risk Assessment
2
2019
3022
0.110
 Why?
Imatinib Mesylate
1
2012
64
0.110
 Why?
Dasatinib
1
2012
45
0.110
 Why?
Aniline Compounds
1
2012
72
0.100
 Why?
Recombinant Fusion Proteins
1
2015
646
0.100
 Why?
Adolescent
5
2022
18219
0.100
 Why?
Thiazoles
1
2012
113
0.100
 Why?
Tumor Microenvironment
1
2015
451
0.100
 Why?
Hematopoietic Stem Cells
1
2015
358
0.100
 Why?
Smoking
1
2019
1457
0.100
 Why?
Proto-Oncogene Proteins c-met
1
2012
69
0.100
 Why?
Propensity Score
3
2017
237
0.100
 Why?
Biological Availability
1
2011
125
0.100
 Why?
Imidazoles
1
2012
214
0.100
 Why?
Carcinoma, Basal Cell
1
2012
67
0.100
 Why?
Phosphatidylinositol 3-Kinase
1
2011
27
0.100
 Why?
Evidence-Based Medicine
2
2012
682
0.100
 Why?
Vascular Endothelial Growth Factor A
2
2024
512
0.090
 Why?
Algorithms
1
2018
1505
0.090
 Why?
Phenotype
1
2018
2892
0.090
 Why?
Brain Neoplasms
1
2018
1010
0.090
 Why?
Adaptation, Psychological
1
2014
541
0.090
 Why?
Genetic Predisposition to Disease
1
2018
2227
0.090
 Why?
Kidney
1
2017
1344
0.090
 Why?
Mice
6
2019
15311
0.080
 Why?
Receptors, Vascular Endothelial Growth Factor
2
2024
102
0.080
 Why?
Models, Biological
2
2020
1689
0.080
 Why?
Multivariate Analysis
3
2017
1458
0.080
 Why?
Neoadjuvant Therapy
2
2022
310
0.080
 Why?
Cohort Studies
4
2022
5051
0.080
 Why?
Caregivers
1
2014
717
0.080
 Why?
Axilla
1
2007
38
0.070
 Why?
Clinical Trials, Phase I as Topic
2
2019
48
0.070
 Why?
RNA, Messenger
1
2014
2632
0.070
 Why?
Mastectomy
1
2007
105
0.070
 Why?
Sentinel Lymph Node Biopsy
1
2007
99
0.070
 Why?
Transcription Factors
1
2014
1557
0.070
 Why?
Stress, Psychological
1
2014
960
0.070
 Why?
Ligation
1
2006
77
0.070
 Why?
Creatinine
2
2018
481
0.070
 Why?
Pain
1
2011
719
0.070
 Why?
Double-Blind Method
2
2021
1670
0.070
 Why?
Lymphatic Metastasis
2
2017
286
0.070
 Why?
Fatal Outcome
1
2006
281
0.070
 Why?
Neoplasm Invasiveness
2
2017
453
0.070
 Why?
Risk Factors
1
2019
8874
0.070
 Why?
Receptors, Progesterone
1
2007
321
0.060
 Why?
Gastrointestinal Hemorrhage
1
2006
102
0.060
 Why?
Skin Neoplasms
1
2012
764
0.060
 Why?
Cell Line, Tumor
3
2018
2814
0.060
 Why?
Glomerular Filtration Rate
2
2018
686
0.060
 Why?
Neoplasm Proteins
1
2007
396
0.060
 Why?
Demography
2
2015
269
0.060
 Why?
Vascular Endothelial Growth Factor Receptor-2
1
2023
86
0.060
 Why?
Recurrence
2
2018
967
0.060
 Why?
Databases, Factual
2
2019
1168
0.060
 Why?
Quality of Life
1
2013
2375
0.050
 Why?
Androgen Antagonists
1
2022
70
0.050
 Why?
Four-Dimensional Computed Tomography
1
2021
27
0.050
 Why?
Immunohistochemistry
2
2018
1657
0.050
 Why?
Pulmonary Ventilation
1
2021
69
0.050
 Why?
Receptors, Androgen
1
2022
132
0.050
 Why?
Radiotherapy Planning, Computer-Assisted
1
2021
122
0.050
 Why?
Receptor, trkC
1
2019
10
0.040
 Why?
Clinical Trials, Phase II as Topic
1
2019
57
0.040
 Why?
Receptor, trkA
1
2019
18
0.040
 Why?
Receptor, trkB
1
2019
28
0.040
 Why?
Trastuzumab
1
2019
90
0.040
 Why?
Extracellular Signal-Regulated MAP Kinases
1
2020
159
0.040
 Why?
Radiotherapy, Image-Guided
1
2018
32
0.040
 Why?
Phthalazines
1
2018
43
0.040
 Why?
Proto-Oncogene Proteins B-raf
1
2020
197
0.040
 Why?
In Situ Hybridization, Fluorescence
1
2019
310
0.040
 Why?
Organic Cation Transporter 2
1
2017
8
0.040
 Why?
Glutathione S-Transferase pi
1
2017
8
0.040
 Why?
Platinum
1
2017
40
0.040
 Why?
Multidrug Resistance-Associated Proteins
1
2017
36
0.040
 Why?
Retroperitoneal Space
1
2017
15
0.040
 Why?
Membrane Glycoproteins
1
2019
439
0.040
 Why?
Organic Cation Transport Proteins
1
2017
28
0.040
 Why?
Urinary Diversion
1
2017
11
0.040
 Why?
National Cancer Institute (U.S.)
1
2017
41
0.040
 Why?
Immunophenotyping
1
2018
274
0.040
 Why?
Margins of Excision
1
2017
32
0.040
 Why?
Social Work
1
2018
72
0.040
 Why?
Tumor Cells, Cultured
1
2019
860
0.040
 Why?
Disease Models, Animal
2
2018
3648
0.040
 Why?
Oncologists
1
2017
31
0.040
 Why?
Laryngectomy
1
2016
19
0.040
 Why?
Anti-Bacterial Agents
1
2006
1500
0.040
 Why?
Hospitals, Veterans
1
2018
239
0.040
 Why?
Cation Transport Proteins
1
2017
99
0.030
 Why?
Carcinogenesis
1
2018
183
0.030
 Why?
Kidney Function Tests
1
2017
160
0.030
 Why?
Pelvis
1
2017
92
0.030
 Why?
Viral Core Proteins
1
2016
21
0.030
 Why?
Radiotherapy, Adjuvant
1
2016
185
0.030
 Why?
Heart
1
2020
623
0.030
 Why?
Regression Analysis
1
2018
971
0.030
 Why?
Internationality
1
2016
149
0.030
 Why?
Random Allocation
1
2016
339
0.030
 Why?
Robotic Surgical Procedures
1
2017
94
0.030
 Why?
Antibodies, Neoplasm
1
2015
30
0.030
 Why?
Biopsy, Large-Core Needle
1
2014
11
0.030
 Why?
Myocardium
1
2020
944
0.030
 Why?
Analysis of Variance
1
2017
1239
0.030
 Why?
Bone Marrow
1
2015
250
0.030
 Why?
Receptor, Notch2
1
2013
14
0.030
 Why?
Receptor Cross-Talk
1
2013
22
0.030
 Why?
Receptor, Notch1
1
2013
61
0.030
 Why?
Transcriptome
1
2018
756
0.030
 Why?
Pandemics
1
2021
1355
0.030
 Why?
Needs Assessment
1
2014
320
0.030
 Why?
Gene Silencing
1
2013
176
0.030
 Why?
Metabolic Clearance Rate
1
2012
110
0.030
 Why?
Psychiatric Status Rating Scales
1
2014
485
0.030
 Why?
Nausea
1
2012
106
0.030
 Why?
Logistic Models
1
2017
1877
0.030
 Why?
Vomiting
1
2012
123
0.020
 Why?
Area Under Curve
1
2012
285
0.020
 Why?
Mice, Nude
1
2013
653
0.020
 Why?
Diarrhea
1
2012
176
0.020
 Why?
Fatigue
1
2012
288
0.020
 Why?
Blotting, Western
1
2013
1172
0.020
 Why?
Drug Administration Schedule
1
2012
723
0.020
 Why?
Cell Proliferation
1
2017
2236
0.020
 Why?
Time Factors
1
2019
6240
0.020
 Why?
Lung
1
2021
3588
0.020
 Why?
Age Factors
1
2016
2951
0.020
 Why?
Colorado
1
2018
4124
0.020
 Why?
Follow-Up Studies
1
2016
4507
0.020
 Why?
Cytokines
1
2015
1852
0.020
 Why?
Surveys and Questionnaires
1
2018
4663
0.020
 Why?
Cross-Sectional Studies
1
2014
4510
0.010
 Why?
Bowles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
See all (339) concept(s)
_
Co-Authors Expand Description
See all (68) people
_
Similar People Expand Description
See all (60) people
_
Same Department Expand Description
Search Department
Physical Neighbors Expand Description
_

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)